Format

Send to:

Choose Destination

Links from PubMed

Malignant tumor of prostate

MedGen UID:
138169
Concept ID:
C0376358
Neoplastic Process
Synonyms: Prostate cancer; Prostatic cancer
Modes of inheritance:
Autosomal dominant inheritance
MedGen UID:
141047
Concept ID:
C0443147
Intellectual Product
Sources: HPO, OMIM, Orphanet
A mode of inheritance that is observed for traits related to a gene encoded on one of the autosomes (i.e., the human chromosomes 1-22) in which a trait manifests in heterozygotes. In the context of medical genetics, an autosomal dominant disorder is caused when a single copy of the mutant allele is present. Males and females are affected equally, and can both transmit the disorder with a risk of 50% for each child of inheriting the mutant allele.
Autosomal dominant inheritance (HPO, OMIM, Orphanet)
SNOMED CT: Malignant tumor of prostate (399068003); Malignant prostatic tumor (399068003); CA - Cancer of prostate (399068003); Cancer of prostate (399068003)
 
Genes (locations): AR (Xq12); BRCA2 (13q13.1); CD82 (11p11.2); CDH1 (16q22.1); CHEK2 (22q12.1); HIP1 (7q11.23); KLF6 (10p15.2); MAD1L1 (7p22.3); MSR1 (8p22); MXI1 (10q25.2); PTEN (10q23.31); ZFHX3 (16q22.2-22.3)
OMIM®: 176807
HPO: HP:0012125

Definition

A cancer of the prostate. [from HPO]

Clinical features

Malignant tumor of prostate
MedGen UID:
138169
Concept ID:
C0376358
Neoplastic Process
A cancer of the prostate.

Term Hierarchy

Conditions with this feature

Malignant tumor of prostate
MedGen UID:
138169
Concept ID:
C0376358
Neoplastic Process
A cancer of the prostate.
Li-Fraumeni syndrome 1
MedGen UID:
322656
Concept ID:
C1835398
Disease or Syndrome
Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome associated with the development of the following classic tumors: soft tissue sarcoma, osteosarcoma, pre-menopausal breast cancer, brain tumors, adrenocortical carcinoma (ACC), and leukemias. In addition, a variety of other neoplasms may occur. LFS-related cancers often occur in childhood or young adulthood and survivors have an increased risk for multiple primary cancers. Age-specific cancer risks have been calculated.
Prostate cancer, hereditary, X-linked 1
MedGen UID:
339479
Concept ID:
C1846279
Neoplastic Process
Prostate cancer is a common disease that affects men, usually in middle age or later. In this disorder, certain cells in the prostate become abnormal and multiply without control or order to form a tumor. The prostate is a gland that surrounds the male urethra and helps produce semen, the fluid that carries sperm.Early prostate cancer usually does not cause pain, and most affected men exhibit no noticeable symptoms. Men are often diagnosed as the result of health screenings, such as a blood test for a substance called prostate specific antigen (PSA) or a medical procedure called a digital rectal exam. As the tumor grows larger, signs and symptoms can include difficulty starting or stopping the flow of urine, a feeling of not being able to empty the bladder completely, blood in the urine or semen, or pain with ejaculation. However, these changes can also occur with many other genitourinary conditions. Having one or more of these symptoms does not necessarily mean that a man has prostate cancer.The severity and outcome of prostate cancer varies widely. Early-stage prostate cancer can usually be treated successfully, and some older men have prostate tumors that grow so slowly that they may never cause health problems during their lifetime, even without treatment. In other men, however, the cancer is much more aggressive; in these cases, prostate cancer can be life-threatening.Some cancerous tumors can invade surrounding tissue and spread to other parts of the body. Tumors that begin at one site and then spread to other areas of the body are called metastatic cancers. The signs and symptoms of metastatic cancer depend on where the disease has spread. If prostate cancer spreads, cancerous cells most often appear in the lymph nodes, bones, lungs, liver, or brain. Bone metastases of prostate cancer most often cause pain in the lower back, pelvis, or hips.A small percentage of all prostate cancers cluster in families. These hereditary cancers are associated with inherited gene mutations. Hereditary prostate cancers tend to develop earlier in life than non-inherited (sporadic) cases.
Prostate cancer/brain cancer susceptibility
MedGen UID:
400334
Concept ID:
C1863600
Finding
Prostate cancer is a common disease that affects men, usually in middle age or later. In this disorder, certain cells in the prostate become abnormal and multiply without control or order to form a tumor. The prostate is a gland that surrounds the male urethra and helps produce semen, the fluid that carries sperm.Early prostate cancer usually does not cause pain, and most affected men exhibit no noticeable symptoms. Men are often diagnosed as the result of health screenings, such as a blood test for a substance called prostate specific antigen (PSA) or a medical procedure called a digital rectal exam. As the tumor grows larger, signs and symptoms can include difficulty starting or stopping the flow of urine, a feeling of not being able to empty the bladder completely, blood in the urine or semen, or pain with ejaculation. However, these changes can also occur with many other genitourinary conditions. Having one or more of these symptoms does not necessarily mean that a man has prostate cancer.The severity and outcome of prostate cancer varies widely. Early-stage prostate cancer can usually be treated successfully, and some older men have prostate tumors that grow so slowly that they may never cause health problems during their lifetime, even without treatment. In other men, however, the cancer is much more aggressive; in these cases, prostate cancer can be life-threatening.Some cancerous tumors can invade surrounding tissue and spread to other parts of the body. Tumors that begin at one site and then spread to other areas of the body are called metastatic cancers. The signs and symptoms of metastatic cancer depend on where the disease has spread. If prostate cancer spreads, cancerous cells most often appear in the lymph nodes, bones, lungs, liver, or brain. Bone metastases of prostate cancer most often cause pain in the lower back, pelvis, or hips.A small percentage of all prostate cancers cluster in families. These hereditary cancers are associated with inherited gene mutations. Hereditary prostate cancers tend to develop earlier in life than non-inherited (sporadic) cases.
Prostate cancer, hereditary, 1
MedGen UID:
419810
Concept ID:
C2931456
Neoplastic Process
Prostate cancer is a common disease that affects men, usually in middle age or later. In this disorder, certain cells in the prostate become abnormal and multiply without control or order to form a tumor. The prostate is a gland that surrounds the male urethra and helps produce semen, the fluid that carries sperm.Early prostate cancer usually does not cause pain, and most affected men exhibit no noticeable symptoms. Men are often diagnosed as the result of health screenings, such as a blood test for a substance called prostate specific antigen (PSA) or a medical procedure called a digital rectal exam. As the tumor grows larger, signs and symptoms can include difficulty starting or stopping the flow of urine, a feeling of not being able to empty the bladder completely, blood in the urine or semen, or pain with ejaculation. However, these changes can also occur with many other genitourinary conditions. Having one or more of these symptoms does not necessarily mean that a man has prostate cancer.The severity and outcome of prostate cancer varies widely. Early-stage prostate cancer can usually be treated successfully, and some older men have prostate tumors that grow so slowly that they may never cause health problems during their lifetime, even without treatment. In other men, however, the cancer is much more aggressive; in these cases, prostate cancer can be life-threatening.Some cancerous tumors can invade surrounding tissue and spread to other parts of the body. Tumors that begin at one site and then spread to other areas of the body are called metastatic cancers. The signs and symptoms of metastatic cancer depend on where the disease has spread. If prostate cancer spreads, cancerous cells most often appear in the lymph nodes, bones, lungs, liver, or brain. Bone metastases of prostate cancer most often cause pain in the lower back, pelvis, or hips.A small percentage of all prostate cancers cluster in families. These hereditary cancers are associated with inherited gene mutations. Hereditary prostate cancers tend to develop earlier in life than non-inherited (sporadic) cases.

Professional guidelines

PubMed

Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL; Guideline Development Group, American College of Medical Genetics and Genomics Professional Practice and Guidelines Committee and National Society of Genetic Counselors Practice Guidelines Committee.
Genet Med 2015 Jan;17(1):70-87. Epub 2014 Nov 13 doi: 10.1038/gim.2014.147. PMID: 25394175
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.
Genet Med 2014 Apr;16(4):338-46. Epub 2013 Sep 26 doi: 10.1038/gim.2013.141. PMID: 24071797
Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH, Penson DF, Zietman AL
J Urol 2013 Aug;190(2):419-26. Epub 2013 May 6 doi: 10.1016/j.juro.2013.04.119. PMID: 23659877Free PMC Article
Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML
J Natl Compr Canc Netw 2011 Nov;9 Suppl 5:S1-32; quiz S33. PMID: 22138009
Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP; National Academy of Clinical Biochemistry.
Clin Chem 2008 Dec;54(12):e11-79. doi: 10.1373/clinchem.2008.105601. PMID: 19042984

Recent clinical studies

Etiology

Smrkolj T, Gubina B, Bizjak J, Kumer K, Fabjan T, Osredkar J
Adv Clin Exp Med 2017 Oct;26(7):1085-1090. PMID: 29211355
Wong KK, Hussain FA, Loo SK, López JI
APMIS 2017 Dec;125(12):1092-1101. Epub 2017 Oct 3 doi: 10.1111/apm.12775. PMID: 28972294
Norström MM, Rådestad E, Sundberg B, Mattsson J, Henningsohn L, Levitsky V, Uhlin M
Oncotarget 2016 Apr 26;7(17):23581-93. doi: 10.18632/oncotarget.8051. PMID: 26993768Free PMC Article
Soylu H, Acar N, Ozbey O, Unal B, Koksal IT, Bassorgun I, Ciftcioglu A, Ustunel I
Pathol Oncol Res 2016 Jan;22(1):87-94. Epub 2015 Sep 5 doi: 10.1007/s12253-015-9983-y. PMID: 26341090
Kim SJ, Jeong TY, Yoo DS, Park J, Cho S, Kang SH, Lee SH, Jeon SH, Lee TY, Park SY
Yonsei Med J 2015 Nov;56(6):1492-6. doi: 10.3349/ymj.2015.56.6.1492. PMID: 26446628Free PMC Article

Diagnosis

Smrkolj T, Gubina B, Bizjak J, Kumer K, Fabjan T, Osredkar J
Adv Clin Exp Med 2017 Oct;26(7):1085-1090. PMID: 29211355
Ronchi A, La Mantia E, Gigantino V, Perdonà S, De Sio M, Facchini G, Franco R, De Chiara A
Diagn Pathol 2017 Jul 7;12(1):50. doi: 10.1186/s13000-017-0640-5. PMID: 28687087Free PMC Article
Sadimin ET, Epstein JI
Hum Pathol 2016 Jun;52:68-73. Epub 2016 Feb 1 doi: 10.1016/j.humpath.2016.01.002. PMID: 26980017
Zhang L, Zhang Q, Li L, Wang Z, Ying J, Fan Y, He Q, Lv T, Han W, Li J, Yang Y, Xu B, Wang L, Liu Q, Sun Y, Guo Y, Tao Q, Jin J
J Mol Med (Berl) 2015 Jun;93(6):691-701. Epub 2015 Feb 5 doi: 10.1007/s00109-015-1255-5. PMID: 25648635
De Berardinis E, Busetto GM, Antonini G, Giovannone R, Di Placido M, Magliocca FM, Di Silverio A, Gentile V
Urologia 2012;79(1):65-8. doi: 10.5301/RU.2012.9099. PMID: 22388992

Therapy

Nesbitt H, Byrne NM, Williams SN, Ming L, Worthington J, Errington RJ, Patterson LH, Smith PJ, McKeown SR, McKenna DJ
Clin Cancer Res 2017 Apr 1;23(7):1797-1808. Epub 2016 Oct 3 doi: 10.1158/1078-0432.CCR-16-1361. PMID: 27697998
Regula N, Häggman M, Johansson S, Sörensen J
Eur J Nucl Med Mol Imaging 2016 Nov;43(12):2131-2138. Epub 2016 Jul 8 doi: 10.1007/s00259-016-3449-7. PMID: 27392615
Kroon J, Buijs JT, van der Horst G, Cheung H, van der Mark M, van Bloois L, Rizzo LY, Lammers T, Pelger RC, Storm G, van der Pluijm G, Metselaar JM
Prostate 2015 Jun;75(8):815-24. Epub 2015 Feb 8 doi: 10.1002/pros.22963. PMID: 25663076Free PMC Article
Zhou R, Lu Z, Liu K, Guo J, Liu J, Zhou Y, Yang J, Mi M, Xu H
Curr Cancer Drug Targets 2015;14(9):860-71. PMID: 25431082Free PMC Article
Zolochevska O, Ellis J, Parelkar S, Chan-Seng D, Emrick T, Wei J, Patrikeev I, Motamedi M, Figueiredo ML
Hum Gene Ther 2013 Dec;24(12):970-81. Epub 2013 Nov 6 doi: 10.1089/hum.2013.091. PMID: 24028178Free PMC Article

Prognosis

Wong KK, Hussain FA, Loo SK, López JI
APMIS 2017 Dec;125(12):1092-1101. Epub 2017 Oct 3 doi: 10.1111/apm.12775. PMID: 28972294
Norström MM, Rådestad E, Sundberg B, Mattsson J, Henningsohn L, Levitsky V, Uhlin M
Oncotarget 2016 Apr 26;7(17):23581-93. doi: 10.18632/oncotarget.8051. PMID: 26993768Free PMC Article
Sadimin ET, Epstein JI
Hum Pathol 2016 Jun;52:68-73. Epub 2016 Feb 1 doi: 10.1016/j.humpath.2016.01.002. PMID: 26980017
Zhang L, Zhang Q, Li L, Wang Z, Ying J, Fan Y, He Q, Lv T, Han W, Li J, Yang Y, Xu B, Wang L, Liu Q, Sun Y, Guo Y, Tao Q, Jin J
J Mol Med (Berl) 2015 Jun;93(6):691-701. Epub 2015 Feb 5 doi: 10.1007/s00109-015-1255-5. PMID: 25648635
De Berardinis E, Busetto GM, Antonini G, Giovannone R, Di Placido M, Magliocca FM, Di Silverio A, Gentile V
Urologia 2012;79(1):65-8. doi: 10.5301/RU.2012.9099. PMID: 22388992

Clinical prediction guides

Smrkolj T, Gubina B, Bizjak J, Kumer K, Fabjan T, Osredkar J
Adv Clin Exp Med 2017 Oct;26(7):1085-1090. PMID: 29211355
Wong KK, Hussain FA, Loo SK, López JI
APMIS 2017 Dec;125(12):1092-1101. Epub 2017 Oct 3 doi: 10.1111/apm.12775. PMID: 28972294
Ronchi A, La Mantia E, Gigantino V, Perdonà S, De Sio M, Facchini G, Franco R, De Chiara A
Diagn Pathol 2017 Jul 7;12(1):50. doi: 10.1186/s13000-017-0640-5. PMID: 28687087Free PMC Article
Norström MM, Rådestad E, Sundberg B, Mattsson J, Henningsohn L, Levitsky V, Uhlin M
Oncotarget 2016 Apr 26;7(17):23581-93. doi: 10.18632/oncotarget.8051. PMID: 26993768Free PMC Article
Zhang L, Zhang Q, Li L, Wang Z, Ying J, Fan Y, He Q, Lv T, Han W, Li J, Yang Y, Xu B, Wang L, Liu Q, Sun Y, Guo Y, Tao Q, Jin J
J Mol Med (Berl) 2015 Jun;93(6):691-701. Epub 2015 Feb 5 doi: 10.1007/s00109-015-1255-5. PMID: 25648635

Recent systematic reviews

Tong X, Li Z, Fu X, Zhou K, Wu Y, Zhang Y, Fan H
Tumour Biol 2014 Sep;35(9):8707-13. Epub 2014 May 29 doi: 10.1007/s13277-014-2040-8. PMID: 24870592
Carvalho FL, Simons BW, Eberhart CG, Berman DM
Prostate 2014 Jun;74(9):933-45. Epub 2014 Apr 16 doi: 10.1002/pros.22811. PMID: 24737393Free PMC Article
van den Bergh RC, Ahmed HU, Bangma CH, Cooperberg MR, Villers A, Parker CC
Eur Urol 2014 Jun;65(6):1023-31. Epub 2014 Jan 28 doi: 10.1016/j.eururo.2014.01.027. PMID: 24491309
Martens-Uzunova ES, Böttcher R, Croce CM, Jenster G, Visakorpi T, Calin GA
Eur Urol 2014 Jun;65(6):1140-51. Epub 2013 Dec 14 doi: 10.1016/j.eururo.2013.12.003. PMID: 24373479
Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B
J Clin Oncol 2014 Jan 20;32(3):229-37. Epub 2013 Dec 9 doi: 10.1200/JCO.2012.48.6431. PMID: 24323034Free PMC Article

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center